Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy

K. A. Jones, MSc, A. D. Small, PhD, S. Ray, PhD, D. J. Hamilton, PhD, W. Martin, PhD, J. Robinson, PhD, N. E. R. Goodfield, MBChB, MRCP, and C. A. Paterson, PhD

Department of Nuclear Cardiology, Glasgow Royal Infirmary, Glasgow, UK
School of Physics and Astronomy, University of Glasgow, Glasgow, UK
School of Mathematics & Statistics, University of Glasgow, Glasgow, UK
School of Medicine, Dentistry & Nursing, University of Glasgow, Glasgow, UK

Received Feb 20, 2020; accepted Jun 29, 2020
doi:10.1007/s12350-020-02277-z

Background. Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function.

Methods. In this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy.

Results. Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups.

Conclusions. The results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF. (J Nucl Cardiol 2022;29:581–9.)

Key Words: RNA: planar • dyssynchrony • diagnostic and prognostic application • image analysis

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12350-020-02277-z) contains supplementary material, which is available to authorized users.
The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.

Reprint requests: K. A. Jones, MSc, Department of Nuclear Cardiology, Glasgow Royal Infirmary, Glasgow; k.jones.3@research.gla.ac.uk
1071-3581/$34.00
Copyright © 2020 The Author(s)
INTRODUCTION

Survival from breast cancer has improved substantially over the last 20 to 30 years due to earlier diagnosis and advances in treatment with adjuvant radiotherapy and chemotherapy. However, cardiotoxicity as a result of this therapy is now the leading cause of morbidity and mortality for survivors.1,2 Radiotherapy and anthracycline/trastuzumab-based chemotherapy regimens have been associated with increased risk of cardiovascular disease.3 Anthracycline-based regimens are associated with the dose-dependent risk of Type 1 cardiotoxicity and heart failure, while trastuzumab is generally associated with reversible Type 2 cardiotoxicity, despite intervention.4 The risk of cancer therapy-related cardiac dysfunction (CTRCD) increases significantly when trastuzumab is combined with anthracyclines.5 Cardiac monitoring is required for patients receiving anthracycline/trastuzumab-based treatments, and currently, this relies on the serial assessment of left ventricular ejection fraction (LVEF). Each patient will have a baseline LVEF measurement, then serial LVEF assessment every 3 months during treatment. The European Society of Cardiology (ESC) guidelines consider a 10% point decrease of LVEF to below the lower limit of normal (< 50%) to be an indicator of cardiotoxicity and recommend treatment is altered or stopped to prevent further left ventricular (LV) dysfunction or the development of symptomatic heart failure.6

One potential limitation of the current guidelines is that LVEF decline is often a late phenomenon. Therefore, it would be useful if we can identify sub-clinical cardiac abnormalities and identify patients who are at higher risk before treatment starts.

Radionuclide ventriculography (RNVG), also commonly known as multi-gated acquisition study (MUGA) or cardiac blood pool imaging, is a well-established technique that can reproducibly measure ejection fraction and is commonly used to assess LV function in patients undergoing cardiotoxic cancer therapy. Echocardiography is also widely used to assess LVEF but is limited by operator variability and poor reproducibility of LVEF measurement, especially in patients post mastectomy who have had reconstructive surgery. LV dyssynchrony can be assessed with a number of imaging techniques. Recently, there has been increased interest in echocardiography deformation assessment with global longitudinal strain (GLS), as an early marker of LV dysfunction for chemotherapy patients.6 This work aims to determine if phase parameters applied to baseline RNVG phase images can measure sub-clinical contraction abnormalities prior to treatment to predict which patients are at a higher risk of CTRCD. At present, there are no published studies investigating RNVG phase parameters as a predictor of CTRCD.

RNVG Phase Images

Phase images, representing the timing of contraction, can be created from RNVG data to provide additional information on ventricular function.7,8 The timing of contraction, relative to the R wave of the ECG, is obtained from the time-activity curve for each pixel in the RNVG image to create a phase map; a higher phase angle indicates delayed contraction within the region. In a phase image with normal contraction, the pixels within the LV should all be a similar phase value, representing synchronous contraction. Regions of dysynchronous contraction will appear as delays in the phase images/histograms. This is illustrated in Figure 1, where the phase for a patient with an aneurysm, left bundle branch block (LBBB), or myocardial infarction (MI) has a distinctly different phase pattern compared to a patient with normal contraction. This technique can also detect more subtle phase abnormalities. Phase data from RNVG images can be quantitatively assessed using the mean and the standard deviation of the phase histogram.

Approximate Entropy

Various measures have been established to quantify dyssynchrony. Most parameters previously investigated are from first-order statistics calculated from the phase histogram such as phase standard deviation (SD). O’Connell et al. derived synchrony to describe the contraction of the left ventricle using the phase and amplitude data extracted from the region of interest, and entropy (from Shannon information measure)9 as a measure of randomness of contraction within the ventricle.10 They demonstrated that synchrony and entropy

| Abbreviations | Definition |
|---------------|------------|
| CTRCD         | Cancer therapy-related cardiac dysfunction |
| LVEF          | Left ventricular ejection fraction |
| RNVG          | Radionuclide ventriculography |
| MUGA          | Multi-gated acquisition study |
| GLS           | Global longitudinal strain |
| LBBB          | Left bundle branch block |
| MI            | Myocardial Infarction |
| ApEn          | Approximate entropy |
| SD            | Standard deviation |
were superior to phase SD for discriminating between normal and abnormal contraction. However, parameters based on first-order statistics such as synchrony, entropy, and phase SD do not take into account the spatial relation between the pixel values. More advanced statistical parameters can be used to quantitatively assess ventricular phase.

Approximate entropy (ApEn) is a regularity statistic developed from Kolmogorov–Sinai entropy by Pincus. When applied to RNVG phase images, ApEn is a statistical measure of dyssynchrony within the ventricle. ApEn calculates the probability that a series of length \( m \) remains similar within a tolerance \( r \) at the next point in the data series, and unlike entropy, takes into account the similarity of adjacent data points and thus can accommodate spatial information more accurately.

ApEn is defined as

\[
\text{ApEn} = -N (N - m) \sum_{i=1}^{N-m} \ln \left( \frac{c_{p+1}(r)}{c_p(r)} \right),
\]

where \( N \) is the length of data, \( m \) is the sequence length, \( r \) is the tolerance, \( c_{p+1}(r) \) is conditional probability that when a sequence is within the tolerance then the next element will also be within tolerance. The pixel values are considered as a data series. Each group of \( 'm' \) pixels will be compared to every other group of \( 'm' \) pixels within the ROI, including itself. If the group is within the tolerance value \( r \), it will be counted. This is carried out for every group of \( 'm' \) pixels then repeated with groups of \( 'm+1' \) to calculate probabilities \( c_p \) and \( c_{p+1} \).

ApEn includes a ‘self match’ of vectors creating a bias towards regularity. Several publications also suggest that ApEn lacks relative consistency, meaning that the value of ApEn can ‘flip’ when the input parameters are varied. For this reason, the input parameters (\( m \) and \( r \)) must be fixed when comparing datasets. At present, there is no established \( m \), \( r \) or normal range for ApEn applied to RNVG phase images. The values of \( m \) and \( r \) that are used will markedly affect the results, so it is essential to optimize the input parameters for the data being considered.

ApEn is well established in other fields including gait analysis and heart rate variability but has not previously been widely investigated for assessing ventricular contraction. Cullen et al. investigated change in ApEn for serial assessment of 8 patients receiving Herceptin. This work found a significant change in ejection fraction and ApEn over the course of treatment, however, further work with a larger patient group is necessary. While change in ApEn has been considered, ApEn as a predictive marker has not yet been investigated.

**METHOD**

ApEn Optimization

Test data were created to simulate patient phase images using in-house code written in R 3.6.3 (R Development Core Team, Vienna, Austria), allowing \( m \) and \( r \) to be tested in a controlled environment. The code allowed the mean and SD in each radial segment to be altered individually, allowing abnormal segments to be introduced. Some publications suggest using a \( r \) value which is 0.1-0.2 SD of the dataset and \( m = 2,12,23 \) although no justification for this choice was found in the literature review. This was used as a starting point to select the test range. A range of \( m \) between 1 and 5, and \( r \) between 0.25 and 21 were tested using the simulated data. Patient phase images representing normal, LBBB, and MI were subsequently used to test the results.

There is a value of \( r \) where the ApEn calculated from both normal and abnormal phase images is equal, as demonstrated in Figure 2. This plot shows an example of the variation in ApEn values comparing a simulated normal and MI phase image across a range of tolerances \( r \). This emphasizes the need for choosing an appropriate value of \( r \) for the data. If a lower value of \( r \) is selected then a higher ApEn is normal, while if a larger value of \( r \) is selected a higher ApEn represents abnormal phase. This is consistent with the work published by Yentes et al. The most important factor in the selection is avoiding the area where abnormal and normal are equal. This ‘flip’ point, where ApEn cannot discriminate between normal and abnormal, will vary depending on how abnormal the phase is, so the range of flip points for the data type must be considered.

After optimization, the final \( m \) and \( r \) values used were \( m = 2, r = 7 \). These values were also tested across the clinical range of left ventricle sizes using simulated data, to ensure consistency with an increase in the number of pixels in the data series, \( N \). The optimization work carried out with both simulated and patient data provides confidence that the selected input values are appropriate.

Data Acquisition

A retrospective study was undertaken to review 193 consecutive female patients (mean age: 54) who had an RNVG scan at Glasgow Western Infirmary Hospital between 2005 and 2008. All patients included in this study had a baseline RNVG before receiving cardiotoxic cancer therapy. Each patient had serial 24-frame gated RNVG scans, acquired at intervals of approximately 3 months for up to 2 years following the baseline study, with each patient having between 2 and 9 RNVGs. Patients with a baseline LVEF of < 55% were excluded from the study.

In-vivo labeling was performed using intravenous administration of pyrophosphate 20 minutes prior to injection of Technetium-99m pertechnetate. The administered dose for each scan was 800 MBq (21.6 mCi).

Each study was acquired with a Picker 3000XP 3-headed gamma camera (Picker International, Cleveland Heights, Ohio, USA) with a low-energy high-resolution collimator. The
gamma camera was positioned to achieve the best septal separation and the scan was acquired for 5 million counts using frame mode acquisition and a matrix size of 64 × 64. The LVEF was assessed by an experienced operator using Picker Lightbox software, with a manual dual region technique to measure the ejection fraction.

For this study only the raw images were available, therefore the baseline study for all 193 patients was reprocessed using MAPS Link medical software. Phase and amplitude images were created from the first-order Fourier harmonic. For each baseline study a single left ventricle region was manually drawn, using the end-diastolic image with reference to the phase and amplitude images. Sixteen patients were excluded at this stage (11 patients with gating problems, which were picked up from the phase image and time-activity curve, 4 patients with a baseline LVEF below 55%, and 1 patient with a baseline scan below diagnostic quality due to poor radiopharmaceutical labeling), leaving 177 patients.

**Data Analysis**

Following each patient’s baseline scan, the LVEF from all subsequent studies was compared to the baseline to establish the maximum LVEF drop. The reported LVEF from the original analysis was used, along with the phase images created using MAPS Link Medical software. Based on the ESC guidelines, patients were split by LVEF decline into 2 groups, those who maintained a normal LVEF and those who had an LVEF drop of over 10% to below 50%.

In-house software written in R 3.6.3 was used to calculate ApEn for the baseline scans. The software creates a data series from the pixels in each region of interest within the phase image, starting from the top left it reads the image from left to right, then right to left on the line below until it reaches the bottom, meaning each group of ‘m’ pixels will be adjacent to each other.

ApEn calculations were carried out on the phase images of the baseline scans, using input parameters m = 2 and r = 7. Synchrony, entropy, and phase SD were also included for comparison.

**Statistical Analysis**

Shapiro–Wilk’s test was used to check the normality of the distribution for each parameter. To test multivariate normality the Henze–Zirkler test was used. Significance testing was performed for each parameter, using the unpaired $t$ test or Wilcoxon-signed-rank test, based on the outcome of the univariate test of normality. Hotelling’s $T^2$ test was used to determine if there was a significant difference between multivariate means of the different populations.

A logistic regression model was fitted in R using all of the phase parameters and the interaction between ApEn and baseline LVEF. A second logistic regression model was created which excluded all of the non-significant variables. A chi-squared test was used to assess the overall significance of the logistic regression models. The area under the receiver operator curve (AUC) and significance was reported for both models.

Random Forest and Naive-Bayes classifiers were fitted using all predictors with the caret package in R, with 10-fold cross-validation and 3 repeats. The AUC was calculated for each classifier.

A $P$ value of $< 0.05$ was considered significant for all tests. All data analysis and statistics were performed in R 3.6.3.

**RESULTS**

Patients were split into 2 groups based on the change in LVEF during treatment. Group 1 maintained a normal LVEF (> 50%) during treatment, and Group 2 had a decline in LVEF of more than 10% to below 50%. The guidelines would recommend that the treatment for Group 2 is altered or stopped. There was no significant difference ($P > 0.05$) in age between the two groups.
ApEn, phase SD, and age were normally distributed while synchrony, entropy, and baseline LVEF were not. Multivariate normality testing for ApEn combined with baseline LVEF revealed that both groups were normally distributed.

The results for ApEn, synchrony, entropy, and phase SD are summarized in Table 1. There was a significant difference ($P < 0.05$) in ApEn and LVEF at baseline between the groups. The combination of ApEn and baseline LVEF was also significantly different between the two groups. The other parameters were not significant.

A boxplot showing the results of ApEn for the groups can be seen in Figure 3. Figure 4 demonstrates how the separation between the groups can be improved by combining the baseline LVEF with the baseline ApEn. This plot indicates that patients with a lower LVEF and higher ApEn at their baseline RNVG (lower right quadrant) are more likely to have an LVEF drop of more than 10% to below 50%.

The fitted logistic regression modelling demonstrated that ApEn, baseline LVEF, and their interaction were significant predictors for CTRCD. The additional variables/predictors synchrony, entropy, and phase SD were not important when ApEn and baseline LVEF are included in the model. The AUC was 0.81 for logistic regression model 1 with all predictors and 0.88 for logistic regression model 2 with only the significant predictors and the interaction between them. A summary of the logistic regression results is shown in Table 2.

The AUC values for the classifiers and logistic regression models are compared in Table 3. Using all predictors, an AUC of 0.87 was achieved under the Random Forest classifier and 0.78 under the Naive-Bayes classifier.

### Table 1. Summary of results for each phase parameter

|                  | Mean ± SD                  | Significance test            | $P$ value |
|------------------|-----------------------------|-----------------------------|-----------|
| **Group 1**      | **Group 2 > 10% drop to LVEF below 50%** |
| **Maintained normal LVEF** | **Maintained normal LVEF**  |                           |           |
| Number of patients | 166                        | 11                         |           |
| Age              | 55 ± 11                     | 56 ± 15                     | Wilcoxon-rank-signed 0.799 |
| Synchrony        | 0.991 ± 0.004               | 0.989 ± 0.004               | Wilcoxon-rank-signed 0.121 |
| Entropy          | 0.559 ± 0.040               | 0.584 ± 0.028               | Wilcoxon-rank-signed 0.054 |
| ApEn             | 0.348 ± 0.107               | 0.418 ± 0.076               | Two sample t test 0.014 |
| Phase SD         | 7.90 ± 1.96                 | 8.91 ± 1.78                 | Wilcoxon-rank-signed 0.094 |
| Baseline LVEF    | 73.5 ± 6.1                  | 64.5 ± 6.7                  | Two sample t test < 0.001 |
| (ApEn, baseline LVEF) |                           |                             | Hotelling’s $T^2$ < 0.001 |

**DISCUSSION**

The results confirm that at the baseline RNVG, there was a significant difference in ApEn between the group with LVEF decline of more than 10% to below 50% (Group 2) and the group that maintained a normal LVEF throughout treatment. ApEn performed better than synchrony, entropy, and phase SD for predicting CTRCD in this dataset.

Improved discrimination between the groups was achieved by considering the combination of baseline LVEF and baseline ApEn. The results suggest that
patients with a lower LVEF and higher ApEn at their baseline RNVG (lower right quadrant in Figure 4) are at a higher risk of developing CTRCD during treatment. Of the patients tested, no one who fell within the top left quadrant in Figure 4 had an LVEF drop to below 50%.

The logistic regression model demonstrated the interaction between ApEn and baseline LVEF was significant between the two groups, suggesting that LVEF combined with ApEn has predictive value at the baseline scan. There was no improvement to the performance of the model when synchrony, entropy, and phase SD were included.

The classifiers performed well, achieving an AUC of 0.78 with Naive-Bayes and 0.87 with Random Forest.

The Random Forest model and logistic regression model 2 performed best on this dataset. However, these results should be interpreted with caution due to the small number of patients who had a significant LVEF decline during treatment. Further work with additional data for testing would be desirable.

Published studies using echocardiography have investigated GLS to assess LV contraction abnormalities and detect sub-clinical changes before any decline in LVEF, with several studies demonstrating that a change in GLS during treatment precedes the drop in LVEF. Ali et al. found that GLS could detect subtle LV abnormalities prior to chemotherapy, and was predictive of cardiac events. They also found a significant difference in baseline LVEF between the groups. Despite there being published results using strain to demonstrate subtle abnormalities before treatment, this is the first RNVG study investigating ApEn as a predictive measure.

ApEn has shown to be promising in this patient cohort and can be calculated quickly without any additional scanning, dose, or processing time. Patients with higher ApEn and low LVEF at baseline may be more susceptible to the cardiotoxic effects of the therapy. Further improvement could potentially be

### Table 2. Logistic regression models

| Predictor                      | Logistic regression model 1 | Logistic Regression model 2 |
|-------------------------------|----------------------------|-----------------------------|
|                               | Coefficient | P value | Coefficient | P value |
| ApEn                          | -116.3147   | 0.044   | -99.1931    | 0.004   |
| Baseline LVEF                 | -0.9568     | 0.014   | -0.8518     | 0.009   |
| ApEn, baseline LVEF interaction | 1.7457     | 0.040   | 1.5253      | 0.033   |
| Synchrony                     | 241.7221    | 0.455   |              |         |
| Entropy                       | 22.0685     | 0.5356  |              |         |
| Phase SD                      | 0.2912      | 0.7761  |              |         |
| Model                         | < 0.001     |         | < 0.001     |         |

### Table 3. Comparison of performance for each model and classifier

| Model                                      | AUC |
|--------------------------------------------|-----|
| Logistic regression 1 (all predictors)     | 0.81|
| Logistic regression 2 (ApEn, baseline LVEF interaction) | 0.88|
| Random forest (all predictors)             | 0.87|
| Naive-Bayes (all predictors)               | 0.78|

**Figure 4.** Baseline LVEF plotted against baseline ApEn for both groups. The dashed lines represent the mean ApEn and mean LVEF of the test population.
achieved by combining ApEn with other clinical parameters and assessing as part of wider texture analysis. Additional data would be necessary to define a decision boundary using these parameters to highlight those most at risk.

Limitations of Study

Of the 177 patients included in this study, only 11 patients had an LVEF decline of more than 10% to below 50%. Due to this study being retrospective, limited information was available detailing the treatment and doses, therefore this study does not discriminate between different chemotherapy regimes. Although the initial results are promising, a prospective study would be desirable to continue this work.

Conclusions

Patients who have a normal LVEF before treatment may have subtle phase abnormalities which can be detected at the baseline test. The results of this study suggest that ApEn combined with the baseline LVEF could potentially predict which patients are at a higher risk of developing CTRCD, as measured by LVEF decline, before treatment commences. If patients who are at a higher risk of CTRCD can be identified, patient treatment and monitoring could become more personalized to the individual, helping to achieve the best outcome for each patient.

NEW KNOWLEDGE GAINED

Combining baseline ApEn with baseline LVEF could potentially predict which patients are at a higher risk of developing CTRCD before cardiotoxic treatment commences.

Disclosures

No financial conflict of interest.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hooning M, Botma A, Aleman BMP, Baaijens MHA, Bartelink H, Klijn JGM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. JNCI 2007;99:365-75.
2. Doyle J, Neugut A, Jacobson J, Grann V, Hershman D. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005;23:8597-605.
3. Boekel NB, Jacobse JN, Schapveld M, Hooning MJ, Grietema JA, Duane FK, et al. Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline based chemotherapy for breast cancer. Br J Cancer 2008;119:408-18.
4. Perez I, Alam S, Hernandez G, Sancassani R. Cancer therapy-related cardiac dysfunction: An overview for the clinician. Clin Med Insights Cardiol 2019;13:117954681986644. https://doi.org/10.1177/1179546819866445.
5. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Askhy M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21.
6. Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the esc committee for practice guidelines. Eur Heart J 2016;37:2768-801.
7. Botvinick EH, Frais MA, Shosa DW, O’Connell JW, Pacheco-Alvarez JA, Scheinman M, et al. An accurate means of detecting and characterizing abnormal patterns of ventricular activation by phase image analysis. Am J Cardiol 1982;50:289-98.
8. Frais MA, Botvinick EH, Shosa DW, O’Connell WI, Scheinman MM, Hattner RS, et al. Phase image characterization of ventricular contraction in left and right bundle branch block. Am J Cardiol 1982;50:95-105.
9. Shannon CE. A mathematical theory of communication. Bell Syst Tech J 1948;27:379-423.
10. O’Connell JW, Schreck C, Moles M, Badwar N, DeMarco T, Olgin J, et al. A unique method by which to quantitate synchrony with equilibrium radionuclide angiography. J Nucl Cardiol 2005;12:441-50.
11. Pincus SM, Gladstone IM, Ehrenkranz RA. A regularity statistic for medical data analysis. J Clin Monit 1991;7:335-45.
12. Yentes JM, Hunt N, Schmid KK, Kaipust JP, McGrath D, Stergiou N. The appropriate use of approximate entropy and sample entropy with short data sets. Ann Biomed Eng 2013;41:349-65.
13. Dawes GS, Mouden M, Sheil O, Redman CW. Approximate entropy, a statistic of regularity, applied to fetal heart rate data before and during labor. Obstet Gynecol 1992;80:763-8.
14. Tullopp MP, Mäkikallio TH, Takala TE, Seppänen T, Huikuri HV. Quantitative beat-to-beat analysis of heart rate dynamics during exercise. Am J Physiol 1996;271:244-52.
15. Georgoulis AD, Moraiti C, Ristanis S, Stergiou N. A novel approach to measure variability in the anterior cruciate ligament deficient knee during walking: The use of the approximate entropy in orthopaedics. J Clin Monit Comput 2006;20:11-8.
16. Khandoker AH, Palaniswami M, Begg RK. A comparative study on approximate entropy measure and poincaré plot indexes of minimum foot clearance variability in the elderly during walking. J Neuroeng Rehabil 2008;5:4.
17. Pincus S, Kalman RE. Irregularity, volatility, risk, and financial market time series. Proc Natl Acad Sci USA 2004;101(38):13709-14.

18. Pincus SM, Goldberger AL. Physiological time-series analysis: What does regularity quantify? Am J Physiol 1994;266(4 Pt 2):1643-56.

19. McKinley RA, McIntire LK, Schmidt R, Repperger DW, Caldwell JA. Evaluation of eye metrics as a detector of fatigue. Hum Factors 2011;53:403-14.

20. Yun K, Park HK, Kwon DH, Kim YT, Cho SN, Cho HJ, et al. Decreased cortical complexity in methamphetamine abusers. Psychiatry Res 2012;201:226-32.

21. Cullen J, Saleem A, Swindell R, Burt P, Moore C. Measurement of cardiac synchrony using approximate entropy applied to nuclear medicine scans. Biomed Signal Process Control 2010;5:32-6.

22. R Core Team, R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2018. http://www.R-project.org/

23. Pincus SM. Approximate entropy as a measure of system complexity. Proc Natl Acad Sci USA 1991;88:2297-301.

24. Whitcher B, Schmid VJ, Thornton A. Working with the DICOM and NIfTI data standards in R. J Stat Softw 2011;44:1-28.

25. Curran J, Hotelling: Hotelling’s $T^2$ Test and Variants. R, package version 1.0-5. https://CRAN.R-project.org/package=Hotelling, 2018.

26. Kuhn M, Wing J, Weston S, Williams A, Keef C, Engelhardt A, et al. caret: Classification and Regression Training. R package version 6.0-84, https://CRAN.R-project.org/package=caret, 2019.

27. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer; 2016.

28. Cheng J, ggval: Annotate Statistical Tests for ’ggplot2’, 2019. R package version 0.2.3.

29. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26:493-8.

30. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375-80.

31. Gripp EA, Oliveira GE, Feijó LA, Garcia MI, Xavier SS, Sousa AS. Global longitudinal strain accuracy for cardiotoxicity prediction in a cohort of breast cancer patients during anthracycline and/or trastuzumab treatment. Am J Cardiol 2018;110:140-50.

32. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596-603.

33. Ali MT, Yucel E, Bouras S, Wang L, Fei HW, Halperrn EF, et al. Myocardial strain is associated with adverse clinical cardiac events in patients treated with anthracyclines. J Am Soc Echocardiogr 2016;29:522-7.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.